Marksans Pharma Limited — Important, 16-07-2025: Updates

Marksans Pharma is holding its AGM to approve FY25 financial results and consider a dividend proposal of ₹0.80/share. The company proposes to appoint Mr. Srinivas Mishra, an Independent Director with extensive corporate finance and risk management expertise. A key development is the amendment to the Employee Stock Option Scheme 2024, extending it to subsidiary employees. This covers 2.3 Cr ungranted options, with a maximum of 1.15 Cr options per employee, aiming to boost group-wide motivation and retention, potentially leading to future equity dilution.